<DOC>
	<DOCNO>NCT01880411</DOCNO>
	<brief_summary>Phase I , Open-Label Study Safety , Tolerability , Immunogenicity Three Dose Regimen Escalating Doses PEK Fusion Protein Vaccine Women LSIL HSIL . PEK fusion protein vaccine ( PEK + GPI-0100 ) safe well tolerated patient low-grade squamous intraepithelial lesion ( LSIL ) high grade squamous intraepithelial lesion ( HSIL ) cervix induces measurable immune response .</brief_summary>
	<brief_title>Phase I , Open-Label Study Safety , Tolerability , Immunogenicity PEK Fusion Protein Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female age 18 45 year Written inform consent accordance institutional guideline Negative pregnancy test LSIL HSIL Papanicolaou ( PAP ) smear within prior 68 week Normal electrocardiogram ( ECG ) , laboratory value ( chemistry , complete blood count ) urinalysis , judge Grade 01 per National Cancer Institute Common Toxicity Criteria ( NCICTC ) perform 30 day prior administration study treatment . Body mass index ( BMI ) ≤32 kg/m2 Women childbearing potential ( WOCBP ) agree use two form medically effective contraception ( e.g . hormonal contraception , intrauterine device , barrier method , spermicide , etc… ) study least 12 week follow completion treatment . Patients agree inform investigator immediately become pregnant study within 12 week follow completion treatment provide information pregnancy , delivery health infant age one month . Able willing comply study procedure Active infection herpes simplex virus ( HSV ) Positive serologic test human immunodeficiency virus ( HIV ) , Hepatitis C virus ( HCV ) , Hepatitis B surface antigen ( HBsa ) Pregnant breastfeed History prior cervical surgical treatment History active autoimmune disease current medical condition require use systemic topical corticosteroid ( exclude steroid contain eye drop inhaled steroid ) immunosuppressive agent within 4 week prior enrollment History cancer ( exclude basal cell carcinoma skin ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Administration blood product within 3 month enrollment Administration vaccine within 6 week enrollment Active infection require antimicrobial treatment Participation study investigational compound device within 30 day prior sign informed consent Any hematologic disorder involve platelet clot abnormality condition require treatment transfusion , anticoagulant platelet inhibitor Active drug alcohol use dependence , opinion investigator , would interfere adherence study protocol Any condition , opinion investigator , would limit evaluation patient .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>PEK fusion protein Healthbanks</keyword>
</DOC>